Levamlodipine oral disintegrating tablet formulation and its preparing method

A technology of levamlodipine and disintegrating tablets, which is applied in the field of oral disintegrating tablets, can solve the problems of inaccurate drug dosage, loss of activity, and side effects, and achieve the effects of accelerating the dissolution of the main drug, ensuring stability, and uniform content of the preparation

Inactive Publication Date: 2006-08-09
SUZHOU DAWNRAYS PHARM CO LTD
View PDF1 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The principle of the foaming agent is to add strong alkaline sodium carbonate or sodium bicarbonate and some acidic compounds to the preparation. These compounds must coexist in the absence of water. However, this technical solution adopts general wet mixing granulation to prepare Its tablet, so it ignores the most essential requirements of the drug, that is, the stability and uniformity of the drug
[0006] First of all, levamlodipine generally exists in the form of active salts, and the best active salts are besylate and maleate, both of which are weakly acidic. It will lose its activity and produce related substances with side effects; secondly, the activity of levamlodipine is very strong, and the dosage commonly used in clinical practice is only a few milligrams. The general preparation process is difficult to ensure the uniformity of the main drug through simple material mixing. , leading to inaccurate doses of medications taken by patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Preparation prescription of the present invention is made up of following components by weight:

[0029] Active salt of levamlodipine (calculated as levamlodipine) 25g

[0030] Mannitol (Pearlitol SD100) 1500g

[0031] Hydroxypropyl Methyl Cellulose E5 50g

[0032] Purified water 500g

[0033] Croscarmellose Sodium 100g

[0034] Micronized silica gel 10g

[0035] Citric acid 14g

[0036] Solid essence 4g

[0037] Hydrogenated Castor Oil 12g

[0038] A total of 10,000 pieces were made

[0039] Process: Feed the prescribed amount of mannitol into the fluidized bed equipped with bottom spray equipment, dissolve or disperse levoamlodipine, stabilizer, hydroxypropyl methylcellulose and micropowder silica gel in pure water, and pour into the fluidized bed Inner Mannitol Top Spray Wrap:

[0040] Air intake volume: about 12.5scfm

[0041] Inlet air temperature: about 65°C

[0042] Air intake dew point: about 15

[0043] Atomizing air flow: about 0.2scfm

[0044] Sp...

Embodiment 2

[0052] Preparation prescription of the present invention is made up of following components by weight:

[0053] Active salt of levamlodipine (calculated as levamlodipine) 50g

[0054] Mannitol (Pearlito SD200) 2000g

[0055] Microcrystalline Cellulose 300g

[0056] Polyvinylpyrrolidone 50g

[0057] Purified water 500g

[0058] Croscarmellose Sodium 100g

[0059] Citric acid 25g

[0060] Flavor 10g

[0061] Micronized silica gel 10g

[0062] Magnesium Stearate 20g

[0063] A total of 10,000 pieces were made

[0064] Process: same as above

Embodiment 3

[0066] Preparation prescription of the present invention is made up of following components by weight:

[0067] Active salt of levamlodipine (calculated as levamlodipine) 100g

[0068] Mannitol (Pearlitol SD200) 2300g

[0069] Microcrystalline Cellulose 300g

[0070] Polyvinylpyrrolidone 50g

[0071] Purified water 200g

[0072] Cross-linked polyvinylpyrrolidone 100g

[0073] Citric acid 40g

[0074] Solid essence 12g

[0075] Micronized silica gel 10g

[0076] Magnesium Stearate 20g

[0077] A total of 10,000 pieces were made

[0078] Process: same as above

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
pore sizeaaaaaaaaaa
Login to view more

Abstract

The present invention discloses a levoamlodipine oral disintegrating tablet preparation and its preparation method. It is made up by using levoamlodipine or its active salt as main medicine, using other ingredients as auxiliary material and adding stabilizing agent, for example citric acid, ascorbic acid, lactic acid, benzenesulfonic acid or maleic acid through a certain preparation process. Besides, said invention also provides the concrete steps of its preparation process.

Description

technical field [0001] The invention relates to a drug orally disintegrating tablet for treating hypertension and angina pectoris, in particular to a levoamlodipine orally disintegrating tablet preparation and a preparation method thereof. technical background [0002] Cardiovascular disease is the number one killer threatening human health, and hypertension is one of the most common diseases. Epidemiological studies show that there are currently 600 million hypertensive patients in the world, and the prevalence of hypertension is about 10%. The national prevalence rate of hypertension is about 12%, and it is as high as 20% in some developed countries in Europe and America. According to national statistics, the number of hypertensive patients in my country has reached 100 million, and more than 3 million people are newly added every year. Hypertension will be a major public health problem facing our country. Complications of hypertension such as s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4422A61K9/20A61P9/10A61P9/12
Inventor 初虹马成孝
Owner SUZHOU DAWNRAYS PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products